There is often synergy between STAT3/5 signaling in cancers cells, which culminates in overlapping target gene spectra such as D type cyclins, c-myc or bcl-2 family members, best exemplified by the mutational landscape of recurrent somatic STAT3 and STAT5B mutations in peripheral T cell lymphoma patients [22]. This evidence concerns the gene STAT5B and cancer.